| Literature DB >> 34520319 |
Yi Li1, Lingzhan Shao2, Yang Mou2, Yan Zhang2, Yong Ping2,3.
Abstract
ABSTRATCIn recent years, emerging studies have observed gut microbiota (GM) alterations in Alzheimer's disease (AD), even in individuals with mild cognitive impairment (MCI). Further, impaired sleep and circadian patterns are common symptoms of AD, while sleep and circadian rhythm disruption (SCRD) is associated with greater β-amyloid (Aβ) burden and AD risk, sometimes years before the clinical onset of AD. Moreover, reports have demonstrated that GM and its metabolites exhibit diurnal rhythmicity and the role of SCRD in dampening the GM rhythmicity and eubiosis. This review will provide an evaluation of clinical and animal studies describing GM alterations in distinct conditions, including AD, sleep and circadian disruption. It aims to identify the overlapping and distinctive GM alterations in these conditions and their contributions to pathophysiology. Although most studies are observational and use different methodologies, data indicate partial commonalities in GM alterations and unanimity at functional level. Finally, we discuss the possible interactions between SCRD and GM in AD pathogenesis, as well as several methodological improvements that are necessary for future research.Entities:
Keywords: Sleep; alzheimer’s disease; animal models; circadian rhythm; gut microbiota; inflammation
Mesh:
Year: 2021 PMID: 34520319 PMCID: PMC8463034 DOI: 10.1080/19490976.2021.1957407
Source DB: PubMed Journal: Gut Microbes ISSN: 1949-0976
Figure 1.A hypothetical model of linking SCRD, GM and AD pathogenesis. SCRD caused by sleep disorders or working night shift impairs brain functions in many ways, one of which acts through GM. SCRD leads to GM dysbiosis, with increase in pathobionts and decrease in beneficial bacteria. In the bottom of the figure, blue color represents symbionts such as beneficial bacteria, while red color represents pathobionts. Integrated gut barrier and BBB normally block pathogens such as bacteria metabolites from entering the brain. However, GM dysbiosis caused by SCRD disrupt gut barrier and BBB by degrading mucin and releasing proinflammatory agents and neurotoxic metabolites. These pathological changes can cause aberrant neuroinflammation, and subsequently lead to Aβ deposition and AD onset
Summary of studies investigating GM alteration in AD
| Reference | Participant/animal model | GM profiling method | Higher or lower bacterial taxa in AD patients/AD animal models | Other major findings | |
|---|---|---|---|---|---|
| Human study | |||||
| 26 | 43 AD patients and 43 age- and gender-matched HC | 16S rRNA gene seq | ↑ | Family: Enterococcaceae, Lactobacillaceae | |
| Genus: | |||||
| Species: | |||||
| ↓ | Family: Lachnospiraceae, Bacteroidaceae, Veillonellaceae | ||||
| Genus: | |||||
| 9 | 30 AD patients, 30 MCI patients, and 30 age- and gender-matched HC | 16S rRNA gene seq | ↑ | Family: Lachnospiraceae, Streptococcaceae, Erysiopelotrichaceae, Coriobacteriaceae, Lactobacillaceae, Bifidobacteriaceae | - Similar alteration of gut and blood microbiota in AD and MCI |
| Genus: | |||||
| ↓ | Family: Alcaligenaceae, Bacteroidaceae, Porphyromonadaceae, Pasteurellaceae, Rikenellaceae | ||||
| Genus: | |||||
| 10 | 33 AD patients, 32 aMCI patients, and 32 age- and gender-matched HC | 16S rRNA gene seq | ↑ | Family: Enterobacteriaceae, Veillonellaceae | - Progressive enrichment of Enterobacteriaceae distinguishes AD from aMCI and HC |
| ↓ | Family: Clostridiaceae, Lachnospiraceae, Ruminococcaceae | ||||
| Genus: | |||||
| 27 | 25 AD patients and 25 age- and gender-matched HC | 16S rRNA gene seq | ↑ | Family: Bacteroidaceae, Rikenellaceae, Gemellaceae | |
| Genus: | |||||
| ↓ | Family: Ruminococcaceae, Bifidobacteriaceae, Clostridiaceae, Peptostreptococcaceae, Mogibacteriaceae, Turicibacteraceae | ||||
| Genus: | |||||
| 28 | 40 Amy+ patients, 33 Amy- patients, and 10 HC | Microbial DNA qPCR Assay Kit | Amy+ | - Escherichia and Shigella correlate with pro-inflammatory IL-1β, NLRP3 and CXCL2 | |
| ↑ | Genus: | ||||
| ↓ | Species: | ||||
| Animal study | |||||
| 29 | Female APP/PS1 mice | 16S rRNA gene seq | ↑ | Family: Erysipelotrichaceae | - Progressive GM shift in AD mice at 3 months |
| Genus: | |||||
| ↓ | Family: Rikenellaceae | ||||
| Genus: | |||||
| 30 | Male SAMP8 mice | 16S rRNA gene seq | ↑ | Genus: | - Altered GM structure with decreased fermentation capacity |
| ↓ | Genus: | ||||
| 31 | Male APP/PS1 mice | 16S rRNA gene seq | ↑ | Family: Verrucomicrobiaceae, Desulfovibrionaceae, Staphylococcaceae, Corynebacteriaceae | - Alleviated AD pathology in AD mice after FMT from WT mice |
| Genus: | |||||
| ↓ | Family: S24_7, Prevotellaceae, Enterococcaceae | ||||
| Genus: | |||||
| 32 | Male SAMP8 mice | 16S rRNA gene seq | ↑ | Genus: | - Decreased spatial learning and memory function in WT pseudo GF mice after FMT from AD mice |
| ↓ | Family: Clostridiales vadinBB60 group, Family XIII, Christensenellaceae, Ruminococcaceae, Desulfovibrionaceae, Deferribacteraceae | ||||
| Genus: | |||||
| 33 | Male APP/PS1 mice | 16S rRNA gene seq | ↑ | Family: Erysiopelotrichaceae, Verrucomicrobiaceae | - Lower level of SCFAs in feces and brain of AD mice |
| Species: | |||||
| ↓ | Genus: | ||||
| Species: | |||||
| 34 | Male APP/PS1 mice | 16S rRNA gene seq | ↑ | Family: Helicobacteraceae, Desulfovibrionaceae, Coriobacteriaceae | - Impaired spatial learning and increased Aβ burden in AD mice |
| Genus: | |||||
| ↓ | Genus: | ||||
| 36 | Male/female APP/PS1 mice | 16S rRNA gene seq | ↑ | Family: Enterobacteriaceae, Staphylococcaceae, Lachnospiraceae, Rikenellaceae | - More severe Aβ pathology induced by FMT from AD mice |
| Genus: | |||||
| ↓ | Family: Bifidobacteriaceae, Coriobacteriaceae, Bacteroidaceae, Prevotellaceae, Turicibacteraceae, Akkermansiaceae | ||||
| Genus: | |||||
| 35 | Female ADLPAPT mice | 16S rRNA gene seq | ↑ | Family: Prevotellaceae, Rikenellaceae | - Damaged gut barrier and chronic inflammation |
| Genus: | |||||
| ↓ | Family: Lactobacillaceae, Turicibacteraceae, Desulfovibrionaceae, S24-7 | ||||
| Genus: | |||||
Note: HC = healthy control, aMCI = amnestic mild cognitive impairment, WT = wild type, FMT = fecal microbiota transplantation, GF = germ free, ↑ = higher, ↓ = lower.
Figure 2.A diagram showing GM compositional changes in AD studies. Increased pro-inflammatory taxa like Erysiopelotrichaceae and Enterobacteriaceae were observed in both AD patients and AD animal models. Escherichia and Shigella of Enterobacteriaceae, which have long been proposed to contribute to series of gastrointestinal diseases, could disrupt the integrity of epithelial cell and lead to leaky gut. Anti-inflammatory Eubacterium and SCFA-producing Ruminococcus were decreased in AD. Two probiotic taxa Lactobacillus and Bifidobacterium have been proven to restore cognitive function and ameliorate Aβ pathology in AD animals
Summary of studies investigating GM intervention and AD
| Reference | Participant/animal model | Treatment | Main findings (Exp |
|---|---|---|---|
| Probiotic supplement | |||
| 51 | AD patients | Duration: 12 weeks | - ↑ cognitive function |
| 54 | AD patients | Duration: 4 weeks | - ↑ |
| 55 | Female AppNL-G-F mice | Duration: 8 weeks | - ↓ intestinal inflammation and gut permeability |
| 52 | Male 3xTg-AD mice | Duration: 4 months | - ↓ cognitive impairment and brain damage |
| 56 | Male ddY mice + intra-hippocampal Aβ injection | Duration: starting 2 days before Aβ injection | - ↓ cognitive impairment |
| 57 | Male Wistar rats + intra-hippocampal Aβ injection | Duration: 8 weeks | - ↑ spatial memory |
| 58 | Male Sprague-Dawley rats | Duration: 41 days | - Disrupted GM in (1) and normalized GM in (2) |
| Antibiotic treatment | |||
| 59 | Male APP/PS1 mice | Duration: post-natal day 14 to day 21 | - Altered GM composition |
| 60 | Male APP/PS1 mice | Duration: lifespan | - Altered GM composition |
| 61 | 5xFAD mice | Duration: 5 months | - ↓ GM abundance |
| 62 | APPPS1-21 mice | Duration: lifespan | - Sex-specific gut microbiota alteration |
| 63 | Male 5xFAD mice | Duration: 2 months | - ↑ ceca size and weight |
| 64 | Male APPPS1-21 mice | Duration: lifespan | - ↑ ceca size and altered GM composition |
| Germ-free animal | |||
| 36 | APP/PS1 mice | GF mice: embryos were washed with Invitrogen and transferred to GF pseudo-pregnant mice | - ↓ Aβ level and Aβ deposition |
| 65 | Female APP/PS1 mice | - Altered GM composition in (1) | |
| 63 | Male 5xFAD mice | GF mice were generated through embryo transfer | - ↑ ceca size and weight |
| FMT and co-housing | |||
| 35 | Female ADLPAPT mice | Duration: 16 weeks | - ↓ cognitive impairment |
| 36 | GF APP/PS1 mice | FMT: oral gavage | - ↑ overall Aβ level in (1) and (2) |
| 61 | WT mice | Duration: 7 months | - ↓ discriminating learning |
| 61 | (1) WT mice + Aβ injection + AD FMT | FMT: oral gavage | - (1) ↑ Th1 cells and ↓ Th2 cells in brain |
| 31 | Male APP/PS1 mice | FMT: oral gavage | - ↓ neuroinflammation |
| 32 | Male pseudo GF WT mice | Duration: 14 days | - ↓ cognitive function in pseudo GF mice |
| 62 | ABX-treated male APPPS1-21 mice | Duration: lifespan | - ↑ Aβ plaque burden |
Note: Exp = experimental group, Con = control group, ABX = antibiotic cocktail, GF = germ-free, SPF = specific pathogen-free, ↑ = increase, ↓ = decrease.
Figure 3.GM intervention studies in AD animal models. (a) Probiotic supplement study: AD mice feed with probiotic strains of Lactobacillus and Bifidobacterium showed reversed cognitive dysfunction, decreased Aβ deposition in brain and lower level of colon inflammation. (b) Antibiotic treatment and germ-free (GF) animal study: antibiotic treated embryo was transferred to pseudo-pregnant mice to generate GF mice. Both GF AD mice and AD mice feed with antibiotic display improved cognitive function, increased Aβ clearance and alleviated neuroinflammation. (c) Fecal microbiota transplantation (FMT) study: FMT from healthy wild-type (WT) donor could restore GM dysbiosis, ameliorate Aβ and tau pathology, and downregulate neuroinflammation in AD mice, whereas GF AD mice receiving FMT from AD mice show aggravated Aβ burden and GM profile similar as observed in AD mice
Summary of studies examining the impact of sleep disturbance on GM and correlation between sleep quality and bacterial taxa
| Reference | Participant/animal model | GM profiling method | GM alterations by sleep disturbance/correlated with poor sleep quality | Other major findings | ||
|---|---|---|---|---|---|---|
| Human study | ||||||
| 71 | 9 healthy males | 16S rRNA gene seq | ↑ | Family: Coriobacteriaceae, Erysiopelotrichaceae | - Increased insulin resistance and fasting insulin level | |
| 72 | 28 healthy adults | 16S rRNA gene seq | + | Genus: | ||
| - | Family: Lachnospiraceae | |||||
| Genus: | ||||||
| 73 | 37 adults aging from 50 to 85 | 16S rRNA gene seq | - | Phylum: Verrucomicrobia, Lentisphaerae | - Better Stroop and Color-Word performance were associated with better sleep quality | |
| 74 | 22 healthy males | 16S rRNA gene seq | + | Family: Lachnospiraceae | ||
| Genus: | ||||||
| - | Genus: | |||||
| Animal study | ||||||
| 75 | Male C57BL/6 J mice | 16S rRNA gene seq | ↑ | Family: Lachnospiraceae, Ruminococcaceae | - Increased food intake, VWAT, inflammation, insulin resistance, and gut permeability | |
| ↓ | Family: Lactobacillaceae, Bifidobacteriaceae | |||||
| 76 | Male C57BL/6 J mice | 16S rRNA gene seq | ↑ | Family: Lachnospiraceae | - Subtle GM alteration by short period of SD | |
| Genus: | ||||||
| ↓ | Genus: | |||||
| 77 | Male Wistar-Kyoto rats | 16S rRNA gene seq | ↑ | Genus: | - Increased mean arterial pressure | |
| ↓ | Genus: | |||||
| Species: | ||||||
| 78 | Male C57BL/6 N mice | 16S rRNA gene seq | ↓ | Family: Bifidobacteriaceae, Lactobacillaceae, Turicibacteraceae | - Reduced fecal bile acid and triterpenoids | |
| Genus: | ||||||
| 79 | Sprague Dawley rats | Distal ileum (D), cecum (C), and proximal colon (P) samples | ASF | ↑ | Family: Enterobacteriaceae (D), S24-7 (D), Ruminococcaceae (C) | - Increased microbial invasion |
| Genus: | ||||||
| ↓ | Family: Lactobacillaceae (D) | |||||
| Genus: | ||||||
| CSF | ↑ | Family: Staphylococcaceae (D), Clostridiaceae (D)(P), Erysipelotrichaceae (P), Ruminococcaceae (P) | ||||
| Genus: | ||||||
| ↓ | Family: Lactobacillaceae (D) | |||||
| 80 | Male Wistar rats | 16S rRNA gene seq | ↑ | Genus: | - Depression-like behavior | |
| ↓ | Genus: | |||||
Note: NS = normal sleep, SD = sleep deprivation, SF = sleep fragmentation, PSQI = Pittsburgh Sleep Quality Index, FMT = fecal microbiota transplantation, GF = germ free, ↑ = increase, ↓ = decrease, + = positively correlated, – = negatively correlated.
Summary of research studying the impact of circadian rhythm disruption on GM
| Reference | Participant/animal model | GM profiling method | GM alterations by circadian rhythm disruption | Other major findings | ||
|---|---|---|---|---|---|---|
| Human study | ||||||
| 87 | 10 healthy males | 16S rRNA gene seq | ↑ | Family: Coriobacteriaceae, Erysipelotrichaceae, Prevotellaceae, Lachnospiraceae | ||
| Genus: | ||||||
| Species: | ||||||
| ↓ | Species: | |||||
| 68 | 2 healthy individuals | 16S rRNA gene seq | ↑ | Phylum: Firmicutes | - Human GM showed diurnal oscillation | |
| ↓ | Phylum: Bacteroidetes | |||||
| 88 | 22 healthy adults | 16S rRNA gene seq | ↑ | Family: Pasteurellaceae, Fusobacteriaceae | - Acute sleep-wake cycle shift had limited impact on GM | |
| Genus: | ||||||
| ↓ | Family: Peptostreptococcacea, Desulfovibrionaceae | |||||
| Genus: | ||||||
| Animal study | ||||||
| 89 | Male C57BL/6 J mice | 16S rRNA gene seq | ↑ | Genus: | - Increased weight gain, inflammation, and insulin resistance | |
| ↓ | Genus: | |||||
| 90 | Male C57BL/6 J mice | 16S rRNA gene seq | ↑ | Species: | - Increased LPS synthesis and decreased SCFAs and indole metabolism | |
| ↓ | Genus: | |||||
| Species: | ||||||
| 91 | Male rats | 16S rRNA gene seq | LL | ↑ | Family: Erysiopelotrichaceae, Bacteroidaceae, Prevotellaceae, Lactobacillaceae | - Increased anxiety and activity |
| Genus: | ||||||
| ↓ | Family: Ruminococcaceae, Porphyromonadaceae | |||||
| Genus: | ||||||
| DD | ↑ | Family: Erysiopelotrichaceae, Prevotellaceae, Lactobacillaceae | - Decreased activity | |||
| Genus: | ||||||
| ↓ | Family: Ruminococcaceae, Porphyromonadaceae | |||||
| Genus: | ||||||
| 68 | WT mice | 16S rRNA gene seq | ↑ | Family: Prevotellaceae, Rikenellaceae | - Mice GM exhibited diurnal oscillation | |
| ↓ | Family: Christensenellaceae, Anaeroplasmataceae | |||||
| Genus: | ||||||
Note: LD = normal light cycle, LL = constant light, DD = constant dark, FMT = fecal microbiota transplantation, GF = germ free, ↑ = increase, ↓ = decrease.
Figure 4.Time-line for the development of AD via SCRD-induced GM dysbiosis. Long-term SCRD (e.g., insomnia, fragmented sleep, night shift work and frequent traveling between time zones) leads to chronic alteration of GM with overabundant pathobionts and reduced beneficial bacteria. GM dysbiosis disrupts gut barrier integrity and facilitates the invasion of pathogens and their metabolite (e.g., LPS, exotoxins and bacterial Aβ). These pro-inflammatory agents induce inflammation responses and compromise BBB structure, leading to neuroinflammation and the onset of early MCI. As MCI develops, progressive enrichment of pathobionts such as Enterobacteriaceae further exacerbate neuroinflammation, cognitive dysfunction and Aβ burden, which in the end contribute to the pathogenesis of AD
Summary of the trend of GM alteration in AD and SCRD
| Implication in health and disease | Taxonomic level | Trend of GM alteration | ||||
|---|---|---|---|---|---|---|
| Family | Genus/Species | AD | SD | CRD | ||
| Human study | ||||||
| Beneficial | Producing SCFAs | Akkermansiaceae | // | N/A | N/A | |
| Inhibiting inflammation and infection | Bacteroidaceae | ↓(S*) | N/A | N/A | ||
| Producing GABA, acetate, and lactate | Bifidobacteriaceae | // | N/A | N/A | ||
| Producing SCFAs | Clostridiaceae | ↓(F**) | N/A | N/A | ||
| Producing butyrate | Eubacteriaceae | ↓(S*) | N/A | N/A | ||
| Producing SCFAs | Lachnospiraceae | // | // | N/A | ||
| Producing GABA, lactate, and amino acid | Lactobacillaceae | // | N/A | N/A | ||
| Producing butyrate | Ruminococcaceae | ↓(F**) | N/A | ↓(G*) | ||
| Producing SCFAs | ↓(G*) | N/A | ||||
| Controversial taxa | Producing propionate | Lachnospiraceae | ↑(G*) | N/A | ↑(F*, G*) | |
| N/A | N/A | ↑(S*) | ||||
| ↑(S*) | N/A | N/A | ||||
| N/A | N/A | ↑(S*) | ||||
| Pathobionts | Positively correlated with IBD | Coriobacteriaceae | ↑(F*) | ↑(F*) | N/A | |
| Producing LPS, bacteria Aβ, and exotoxin | Enterobacteriaceae | ↑(F*, G*) | N/A | ↑(G*) | ||
| ↑(F*, G*) | N/A | ↑(G*) | ||||
| Highly immunogenic | Erysiopelotrichaceae | ↑(F*) | ↑(F*) | ↑(F*) | ||
| Prevotellaceae | N/A | ↑(G*) | ↑(F*) | |||
| Animal study | ||||||
| Beneficial bacteria | Producing SCFAs | Akkermansiaceae | // | ↓(G*) | N/A | |
| Inhibiting inflammation and infection | Bifidobacteriaceae | ↓(G*) | ↓(F**, G*) | N/A | ||
| Producing butyrate | Eubacteriaceae | ↓(G*) | N/A | ↓(S*) | ||
| ↓(G*, S*) | N/A | |||||
| Producing SCFAs | Lachnospiraceae | // | // | // | ||
| Producing butyrate | ↓(G*) | ↓(G*) | N/A | |||
| Producing GABA, lactate, and amino acid | Lactobacillaceae | ↓(G*) | ↓(F****, G**) | // | ||
| Producing SCFAs | Ruminococcaceae | ↓(G****) | ↑(F***, G*) | ↓(F**, G**) | ||
| Negatively correlated with IBD | S24-7 | ↓(F***) | N/A | N/A | ||
| Negatively correlated with IBD, ASD | Turicibacteraceae | ↓(F**, G**) | ↓(F*, G*) | ↓(G*) | ||
| Controversial taxa | Producing propionate | Lachnospiraceae | // | ↑(F***) | // | |
| N/A | N/A | ↑(S*) | ||||
| Pathobionts | Producing LPS, bacteria Aβ, and exotoxin | Enterobacteriaceae | ↑(F*) | ↑(F*, G*) | N/A | |
| ↑(F*, G*) | N/A | |||||
| Highly immunogenic | Erysiopelotrichaceae | ↑(F**) | ↑(F*) | ↑(F**) | ||
| Prevotellaceae | // | ↑(G**) | ↑(F***, G**) | |||
| Producing bacterial Aβ and toxin | Staphylococcaceae | ↑(F**, G**) | ↑(F*) | N/A | ||
Note: ↑ = increase, ↓ = decrease, // = both increase and decreased were reported, N/A = not reported, F = family level, G = genus level, S = species level, * = number of study.
Figure 5.Schematic diagram of how SCRD contributes to AD pathogenesis through GM dysbiosis. SCRD, such as sleep deprivation, sleep fragmentation and jet lag, disrupts gut homeostasis with increased pathobionts (e.g., Enterobacteriaceae, Erysiopelotrichaceae and Prevotellaceae) and decreased beneficial bacteria (e.g., Eubacteriaceae, Ruminococcaceae and other SCFA-producing taxa). On one hand, pathobionts could damage gut barrier and cause leaky gut through the degradation of mucus layer. Pathogens and their metabolites induce pro-inflammatory responses and lead to increased BBB permeability. Bacteria-derived Aβ and LPS invade CNS and are associated with neuroinflammation and Aβ pathology. On the other hand, the compromised functions of beneficial bacteria (e.g., inhibiting infection, promoting mucin expression, producing neuromodulators and anti-inflammation SCFAs) are overwhelmed by overabundant pathobionts. Thus, the elevated neuroinflammation and aggravated Aβ burden facilitate the onset of AD